Börskollen
Pressmeddelanden från Oncoinvent
20 maj 20:54
OncoinventOncoinvent ASA: Grant of share options to member of the Board following AGM20 maj 11:15OncoinventOncoinvent ASA: Minutes from Annual General Meeting05 maj 10:26OncoinventOncoinvent ASA: Share capital decrease completed29 apr 07:00OncoinventOncoinvent presents corporate update in live webcast28 apr 12:47OncoinventOncoinvent ASA: Notice of Annual General Meeting23 apr 07:00OncoinventOncoinvent ASA: Invitation to business update Wednesday 29 April 202622 apr 16:31OncoinventOncoinvent ASA: Annual Report for 202519 mar 07:00OncoinventOncoinvent secures new patent expanding protection for Radspherin[®]11 mar 22:34OncoinventOncoinvent ASA: Grant of share options to the CEO26 feb 07:00OncoinventOncoinvent ASA: Second half 2025 results17 feb 07:00OncoinventOncoinvent to Present Positive 24-month Follow-up Data from Phase 1 Ovarian Cancer Study of Radspherin[®] at ESGO 202616 feb 07:00OncoinventOncoinvent ASA: Announces webcast presentation of second half 2025 results on Thursday 26 February 202629 jan 07:00OncoinventFour additional sites open for recruitment in Oncoinvent’s Phase 2 trial08 jan 13:42OncoinventOncoinvent ASA: Minutes from Extraordinary General Meeting22 dec 2025 18:09OncoinventOncoinvent ASA: Grant of share options – mandatory notification of trade08 dec 2025 07:00OncoinventOncoinvent Announces Publication of Phase 1 Study Results for Radspherin® in Ovarian Cancer in Gynecologic Oncology17 nov 2025 06:30OncoinventOncoinvent ASA: Commencement of the subscription period for the Rights Issue14 nov 2025 10:56OncoinventOncoinvent ASA – Receipt of subscription rights in the rights issue by primary insiders and their close associates03 nov 2025 12:55OncoinventReminder: Invitation to presentation of Q3 2025 company update on November 4[th], 202503 nov 2025 08:55OncoinventMandatory notification of trade31 okt 2025 08:30OncoinventOncoinvent appoints Dr. Ramzi Amri as new CFO29 okt 2025 17:38OncoinventMerger of BerGenBio and Oncoinvent completed29 okt 2025 15:16OncoinventOncoinvent Presents Final Safety and Efficacy Results from the Phase 1/2a Trial of Radspherin® to Treat Colorectal Cancer at the 15th PSOGI International Congress on Peritoneal Surface Malignancies24 okt 2025 07:59OncoinventBerGenBio and Oncoinvent – Key Dates for Completion of Merger08 okt 2025 07:00OncoinventOncoinvent Reports Positive Final Data from Phase 1 Trial of Radspherin® to Treat Ovarian Cancer17 sep 2025 08:56OncoinventOncoinvent ASA: Updated information regarding the contemplated Rights Issue and Merger17 sep 2025 08:55OncoinventOncoinvent ASA: Updated Key Information related to the contemplated Rights Issue29 aug 2025 07:00OncoinventThor Medical and Oncoinvent Enter Strategic Thorium-228 Supply Agreement27 aug 2025 07:00OncoinventOncoinvent ASA half-yearly report: Strong focus on financial discipline and advancing Phase 2 program in ovarian cancer04 aug 2025 13:53OncoinventOncoinvent shareholders approve the merger plan with BerGenBio03 jul 2025 15:45OncoinventOncoinvent ASA: Notice of Extraordinary General Meeting30 jun 2025 22:11OncoinventAnnouncement of fully underwritten rights issue30 jun 2025 22:01OncoinventBerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue
OncoinventOncoinventOncoinventOncoinventOncoinventOncoinventOncoinventOncoinventOncoinventOncoinventOncoinventOncoinventOncoinventOncoinventOncoinventOncoinventOncoinventOncoinventOncoinventOncoinventOncoinventOncoinventOncoinventOncoinventOncoinventOncoinventOncoinventOncoinventOncoinventOncoinventOncoinventOncoinventOncoinvent